Search for a trial

Evaluation of Prostate-Specific Antigen Glycomics Assay for the Early Detection of Prostate Cancer

The current research is focused on finding a method that is able to better stratify the patients. A possible method could be to study PSA in more detail, specifically the modifications which are present on the protein. One of these modifications is…

Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic
Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)

This study has been transitioned to CTIS with ID 2023-506987-15-00 check the CTIS register for the current data. 1) Objective: To evaluate the safety and tolerability of the pembrolizumab combination therapy.2) Objective: To estimate PSA response…

Tolerability of concurrent EBRT + Lu-PSMA for node-positive prostate cancer (PROQURE-1)

This study has been transitioned to CTIS with ID 2024-514168-15-00 check the CTIS register for the current data. Primary: To determine the maximum tolerated dose (MTD) of 1 or 2 cycli Lu-PSMA when given concurrent with EBRT+ADT. Secondary: To…

18F-fluciclovine PET/CT and 18F-DCFPyL PET/CT in patients with biochemical recurrence of disease after radical prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.

To head-to-head compare the per patient detection rate of 18F-Fluciclovine PET/CT versus 18F-DCFPyL PET/CT in patients with BCR of disease after radical prostatectomy.

Prostate cancer Research International: Active Surveillance (PRIAS) MRI study

To study the value of mpMRI with subsequent targeted biopsies after inclusion to more accurately grade prostate cancers of men on active surveillance. Furthermore, the value of mpMRI in reducing the number and amount of biopsies will be studied.

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Prostate Specific Membrane Antigen (PSMA) Half Life Extended (HLE) Bispecific T-cell Engager (BiTE) AMG 160 in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Main objective:Parts 1, 3, 4, 5 en 6: AMG 160 monotherapy• Evaluate the safety and tolerability of AMG 160 in adult subjects• Part 1 only: Determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D)Part 2: AMG 160 in combination…

A Master Protocol Evaluating the Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC);- Subprotocol A: A Phase 1b Study Evaluating the Safety and Efficacy of AMG 160 in Combination With Enzalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Subprotocol B: A Phase 1b Study Evaluating the Safety and Efficacy of AMG 160 in Combination With Abiraterone in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Primary objective: To evaluate the safety, tolerability, and maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of investigational therapies in subjects with metastatic castration-resistant prostate cancer (mCRPC).Secondary objective:*…

A FEASIBILITY STUDY OF 177LU-PSMA RADIOLIGAND THERAPY ALTERNATED WITH RADIUM-223 IN PATIENTS WITH BONE-METASTATIC, OLIGO-METASTATIC HORMONE-SENSITIVE PROSTATE CANCER AFTER CURATIVE THERAPY. THE DUET STUDY

This study has been transitioned to CTIS with ID 2024-518985-29-02 check the CTIS register for the current data. To prospectively investigate if a treatment strategy in which two types of cytotoxic RLT, i.e., an alpha-emitter and a beta-emitter, are…

A randomized, open label, Phase IIB trial of Optimal Sequencing of Treatment Options for Poor Risk Metastasized Castration Resistant Prostate Cancer Previously Treated with Docetaxel (OSTRICh trial)

Primary: * To assess Clinical Benefit Rate (CBR) in patients with mCRPC and poor prognostic factors treated with cabazitaxel or novel hormonal agents (abiraterone OR enzalutamide) as second-line therapy.Secondary: * To formally compare CBR in both…

Effectiveness of focal therapy in men with prostate cancer (ENFORCE)

We hypothesize that a significant proportion of the patients will benefit more from focal therapy as compared to usual care in terms of morbidity and quality of life, without compromising oncological effectiveness. Primary objective: To study the…

Tracer-Based Imaged Guided Surgery for Recurrent Prostate Cancer: A Prospective Randomized Controlled Trial - TRACE II

Evaluate the clinical progression free survival after randomization to either 6 months of androgen deprivation therapy (ADT) or 6 months of ADT plus a 99mTechnetium (99mTc)-based PSMA-radioguided salvage surgery.

Transperineal Laser Ablation for treatment of LUTS due to benign prostatic obstruction

The primary objective of this study is to prove feasibility and safety of TPLA for LUTS due to BPO in healthy men. The secondary objectives are to determine functional voiding, erectile outcomes and changes on imaging.

RObotic mri-guided high dose rate Brachytherapy Needle implantation in the proState - a proof of concept study

To investigate the technical feasibility of inserting a brachytherapy needle into the prostate to a defined tumour target point using a robotic device.

Clinical validation of transrectal multiparametric ultrasound imaging strategy (PCaVision) for the detection of clinically significant prostate cancer: a European head-to-head comparison with the MRI-based strategy in primary diagnosis and in an active surveillance population

The primary objective is to demonstrate non-inferiority of the detection rate of clinically significant prostate cancer (defined as GG>=2) in targeted biopsies based on PGaVision imaging (PCaVision pathway) in comparison with the detection…

Addition of a Focal boost In external beam Radiotherapy for locally advanced prostate cancer by online adaptive MR-guided radiotherapy (AFFIRM trial)

In the present study the clinical feasibility and safety of MR-guided focal boost radiotherapy for patients with locally advanced prostate cancer will be evaluated.

Magnetic resonance imaging-guided focal laser ablation of prostate cancer

Primary objectiveThe primary objective for this phase IIa study is to investigate the feasibility, usability and safety of CLS MR-guided FLA in the treatment of prostate cancer.Secondary objectiveTo assess tumor response and functional outcomes

An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer-sponsored studies

This study has been transitioned to CTIS with ID 2022-502084-38-00 check the CTIS register for the current data. Primary- Continuation of treatment- SafetySecondairy- Documentation of tolerability

Clinical validation of transrectal multiparametric ultrasound imaging strategy (PCaVision) for the detection of clinically significant prostate cancer: a head-to-head comparison with the MRI-based strategy

• The primary objective is to demonstrate non-inferiority of the detection rate of clinically significant prostate cancer (defined as GG >= 2) in targeted biopsies based on PCaVision imaging (PCaVision pathway) in comparison with the…

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Delta-like Protein 3 Half-life Extended Bispecific T-cell Engager AMG 757 in Subjects with De Novo or Treatment Emergent Neuroendocrine Prostate Cancer

This study has been transitioned to CTIS with ID 2024-513316-10-00 check the CTIS register for the current data. Primary:• To Evaluate the safety and tolerability of tarlatamab • Determine the maximum tolerated dose (MTD) or recommended phase 2 dose…

177Lu-PSMA RADIOLIGAND THERAPY IN PATIENTS WITH LYMPH NODE METASTATIC HORMONE-SENSITIVE PROSTATE CANCER UNDERGOING ROBOT-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY AND EXTENDED PELVIC LYMPH NODE DISSECTION

To investigate if surgery is feasible and safe in patients with newly diagnosed lymph node metastatic HSPCa who have received two cycles of (neo-adjuvant) systemic 177Lutetium (Lu)-labeled prostate-specific membrane antigen (PSMA) radioligand…